It’s a sell­er’s world in biotech M&A, and No­var­tis CEO Vas Narasimhan has his check book out and pen ready

7 years ago
Deals

Vi­iV's Dova­to wins speedy US ap­proval with PRV, em­pow­er­ing GSK to mus­cle in­to Gilead­'s HIV em­pire

7 years ago
Discovery

FDA snubs Zo­genix's an­ti-seizure drug, not hap­py with some slop­py, in­ad­e­quate R&D work

7 years ago
R&D

Unit­ed kills its PhI­II PAH drug af­ter it fails Ty­va­so com­bo study

7 years ago
R&D

TKI biotech lays out plans to raise about $125M in IPO; Hookipa sets terms for up­sized $100M IPO

7 years ago
News Briefing

Bat­tered and out of op­tions, His­to­gen­ics turns to eye drug de­vel­op­er Ocu­gen for re­verse merg­er

7 years ago
Deals
Pharma

Can Tre­vi make it through the IPO win­dow with an old opi­oid that failed their key PhII?

7 years ago
Financing

Cel­gene, Ac­celeron sub­mit FDA ap­pli­ca­tion for billed block­buster lus­pa­ter­cept — will they get pri­or­i­ty re­view?

7 years ago
Pharma

Go­ing gang­busters: The top 20 biotech plat­form deals by up­front cash

7 years ago
Pharma

Tapped as Kymab CEO, Si­mon Sturge jumps back in­to biotech pond as Dave Chiswell steps aside

7 years ago
People

An­oth­er play­er in the gene ther­a­py field is gun­ning for the Duchenne MD crown — and here’s what they're bet­ting ...

7 years ago
Bioregnum
Cell/Gene Tx

At a cool $1B-plus in up­front, eq­ui­ty and ear­ly-stage cash, Re­gen­eron ties a block­buster R&D part­ner­ship knot with ...

7 years ago
R&D
Pharma

Rat study sug­gests Al­ler­gan's failed an­ti­de­pres­sant ra­pastinel may work as opi­oid ad­dic­tion treat­ment

7 years ago
R&D
Discovery

Bay­er re­ports cy­ber at­tack point­ed to Chi­nese hack­ers; FDA pro­longs re­view of Dai­ichi Sanky­o's AML drug

7 years ago
News Briefing

Out­side re­view con­firms top Memo­r­i­al Sloan Ket­ter­ing ex­ec­u­tives flout­ed con­flicts-of-in­ter­est poli­cies — re­port

7 years ago
People

Peer Re­view: Plot­ting US moves, Zealand Phar­ma poach­es Al­ny­lam's Em­manuel Du­lac as new CEO

7 years ago
Peer Review

Guard­ing a $2 bil­lion fran­chise op­er­a­tion, Gilead hus­tles up its sN­DA for De­scovy. But will it work?

7 years ago
R&D

Jazz, Lund­beck and Alex­ion pay $122M+ to re­solve DoJ claims of us­ing char­i­ties as 'con­duit­s' to stim­u­late use of ...

7 years ago
Pharma

The case of the miss­ing PD-L1: UCSF sleuths de­vise a new ‘tu­mor cell vac­cine’ and a check­point strat­e­gy that ...

7 years ago
Discovery

The point of no re­turn for Mer­ri­mack? Can­cer drug de­vel­op­er ax­es yet an­oth­er drug and more staff

7 years ago
R&D

To counter a law­suit, Bris­tol-My­ers out­lines how the big Cel­gene buy­out will show­er $187M-plus on Mor­gan Stan­ley

7 years ago
Deals

Bil­lions on the line, No­var­tis and Am­gen ex­change broad­sides as Aimovig part­ner­ship erupts in­to a le­gal war

7 years ago
Pharma

Cit­ing patent in­fringe­ment, Lipocine sues Clarus; Sang­amo, DBV un­veil share of­fer­ings

7 years ago
News Briefing

Jeff Be­zos teams with Bill Gates to fund new and bet­ter ways to di­ag­nose Alzheimer’s

7 years ago
Discovery
First page Previous page 960961962963964965966 Next page Last page
A service from the Financial Times